Current role of portal vein embolization/hepatic artery chernoembolization
被引:40
作者:
论文数: 引用数:
h-index:
机构:
Kokudo, N
[1
]
Makuuchi, M
论文数: 0引用数: 0
h-index: 0
机构:
Univ Tokyo, Dept Surg, Hepatobiliary Pancreat Surg Div, Bunkyo Ku, Tokyo, JapanUniv Tokyo, Dept Surg, Hepatobiliary Pancreat Surg Div, Bunkyo Ku, Tokyo, Japan
Makuuchi, M
[1
]
机构:
[1] Univ Tokyo, Dept Surg, Hepatobiliary Pancreat Surg Div, Bunkyo Ku, Tokyo, Japan
This article presents an overview of Indications, methods, and results of portal vein embolization (PVE) and transarterial chemoembolization (TACE) for hepatobiliary malignancies. PVE is applied mainly to increase the safety of major hepatic resection in patients with hilar cholangiocarcinoma, hepatocellular carcinoma (HCC), or metastatic liver tumors. Hepatic arterial embolization causes selective ischemia of the liver tumor and enhances the cytotoxicity of the chemotherapeutic agent administered concomitantly. Survival benefit of TACE in patients with unresectable or recurrent HCC has been demonstrated.